POMDOCTOR LIMITED American Depositary Shares (POM)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am a value investor who looks for durable earnings, honest accounting, and a price that discounts the future conservatively. Pomdoctor is an online B2C pharmaceutical and chronic-disease platform in China, with only 165 employees and a $49.2M market cap at the 2026-10-13 close of $0.75. The figures I have do not describe a healthy enterprise. At that close, the FairStock-calculated P/E is -0.11, ROCE is -352.09%, Piotroski F-Score is 2/9, and Altman Z-Score is -33.44. Those are not the marks of a business with a moat, pricing power, or a margin of safety. The FairStock Score is 20/100. The absence of P/B, ROE, D/E, revenue growth, and profit growth data leaves me without the basic tools I need to value the enterprise. There are only 0 years of filed results, so the computed Lynch category is none; I cannot assess a multi-year growth trajectory. The 52-week range of $0.06 to $6.43 tells me the market has repriced this stock violently, which is usually a sign of speculation rather than stable compounding. A negative P/E means the earnings figure used in that FairStock calculation is negative, so the P/E is not a valuation anchor. The company pays no dividend. Its industry—pharmaceutical retail and online chronic care in China—could be large, but without revenue, profit, or cash-flow data, I cannot confirm that the platform has scale, retention, or bargaining power. Graham would distinguish investment from speculation. Here the evidence points to speculation. I would need several years of audited results, positive returns on capital, and a balance sheet that does not scream distress before I could call this a business rather than a lottery ticket.

In plain English: Pomdoctor runs an online medical and pharmacy platform in China focused on chronic diseases, connecting patients, doctors, and drug sellers. The business looks weak because it is losing money and has very little reported financial history. The stock price of $0.75 on 2026-10-13 may look low, but with losses and no payout, it does not look clearly cheap based on the figures given.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer